Company profile for Frequency Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our initial therapeutic focus is for sensorineural hearing loss (SNHL), which is the most prevalent type of hearing loss. SNHL is typically caused by the permanent loss of sensory hair cells in the cochlea within the ear. FX-322, our lead product candidate...
We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our initial therapeutic focus is for sensorineural hearing loss (SNHL), which is the most prevalent type of hearing loss. SNHL is typically caused by the permanent loss of sensory hair cells in the cochlea within the ear. FX-322, our lead product candidate, is intended to regenerate hair cells through the activation of progenitor cells already present in the cochlea. We are exploring ways in which our PCA platform may be beneficial in the treatment of multiple sclerosis.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
19 Presidential Way Woburn, MA 02801
Telephone
Telephone
781-315-4600
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://endpts.com/progentos-emerges-with-65m-for-multiple-sclerosis-trials-with-ip-from-frequency/

ENDPTS
20 May 2024

https://www.globenewswire.com//news-release/2023/11/03/2773416/0/en/UPDATE-Korro-Bio-and-Frequency-Therapeutics-Announce-Closing-of-Merger-and-Private-Placement-of-117-Million.html

GLOBENEWSWIRE
03 Nov 2023

https://www.businesswire.com/news/home/20230810506865/en

BUSINESSWIRE
10 Aug 2023

https://www.businesswire.com/news/home/20230714609713/en

BUSINESSWIRE
14 Jul 2023

https://www.businesswire.com/news/home/20230310005054/en

BUSINESSWIRE
10 Mar 2023

https://www.businesswire.com/news/home/20230227005295/en

BUSINESSWIRE
27 Feb 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty